載入中
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
前收盤價
US$1.03
−US$0.05 · -4.63%
盤中時間採用ET。市場資料可能有所延遲。
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
日內區間
目前US$1.03
52週區間
目前US$1.03
盤中時間採用ET。市場資料可能有所延遲。
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
日內區間
目前US$1.03
52週區間
目前US$1.03
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 713.7萬 USD | 2096.8萬 USD | 4186.7萬 USD | 2302.8萬 USD |
| 銷貨成本 | 9.5萬 USD | 81.2萬 USD | 643.3萬 USD | 751.4萬 USD | 155.4萬 USD |
| 毛利 | −9.5萬 USD | 632.5萬 USD | 1453.5萬 USD | 3435.3萬 USD | 2147.4萬 USD |
| 研究與開發 | 1801.1萬 USD | 3275.5萬 USD | 1.08億 USD | 9175.9萬 USD | 8257.8萬 USD |
| 銷售、一般及管理費用 | 873.7萬 USD | 2638.8萬 USD | 2764.9萬 USD | 3012.9萬 USD | 2797.9萬 USD |
| 營業費用 | 2674.8萬 USD | 6210.6萬 USD | 1.36億 USD | 1.22億 USD | 1.11億 USD |
| 利息收入 | 137.5萬 USD | 282.8萬 USD | 131.8萬 USD | 65.4萬 USD | 60.3萬 USD |
| 利息支出 | — | 847.3萬 USD | — | 3000 USD | — |
| 折舊和攤銷 | 9.5萬 USD | 19.2萬 USD | 25.9萬 USD | 8.5萬 USD | 155.4萬 USD |
| 營業利益 | −2674.8萬 USD | −5578.1萬 USD | −1.21億 USD | −8753.5萬 USD | −8908.3萬 USD |
| 淨利 | −1821.4萬 USD | −7086.7萬 USD | −1.19億 USD | −8547.4萬 USD | −8844.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年4月16日 | 1:3 | — | — |
股票分割 | 2024年12月31日 | 1:12 | — | — |
已生效 2025年4月16日
1:3
已生效 2024年12月31日
1:12
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
